Panel AI

Apa yang dipikirkan agen AI tentang berita ini

Despite a modest increase in institutional holdings, the panel is cautious about AbbVie's future due to the looming Humira patent cliff, integration risks from recent acquisitions, and potential capital structure issues. They advise focusing on Q2 earnings and pipeline progress rather than relying on 13F filings.

Risiko: Integration delays or failures of recent acquisitions (ImmunoGen and Cerevel) could spike the interest coverage ratio below 3x, pressuring the balance sheet and potentially capping multiple expansion.

Peluang: Successful integration and growth of the Skyrizi and Rinvoq pipelines could offset the Humira patent cliff and drive long-term EPS growth.

Baca Diskusi AI
Artikel Lengkap Nasdaq

Di Holdings Channel, kami telah meninjau kumpulan terbaru dari 51 pengajuan 13F yang paling baru untuk periode pelaporan 03/31/2026, dan menemukan bahwa AbbVie Inc (Simbol: ABBV) dipegang oleh 34 dana ini. Ketika manajer hedge fund tampaknya berpikir sama, kami merasa merupakan ide yang baik untuk melihat lebih dekat.

Sebelum kami melanjutkan, penting untuk dicatat bahwa pengajuan 13F tidak menceritakan keseluruhan cerita, karena dana-dana ini hanya diwajibkan untuk mengungkapkan posisi *long* mereka kepada SEC, tetapi tidak diwajibkan untuk mengungkapkan posisi *short* mereka. Sebuah dana yang membuat taruhan bearish terhadap saham dengan melakukan short calls, misalnya, mungkin juga memegang sejumlah saham saat mereka berdagang di sekitar posisi bearish mereka secara keseluruhan. Komponen long ini dapat muncul dalam pengajuan 13F dan semua orang mungkin berasumsi bahwa dana tersebut bullish, tetapi ini hanya menceritakan sebagian dari cerita *karena sisi bearish/short dari posisi tersebut tidak terlihat*.

Setelah memberikan peringatan tersebut, kami percaya bahwa melihat *kelompok* pengajuan 13F dapat mengungkapkan, terutama saat membandingkan satu periode kepemilikan dengan periode lainnya. Di bawah ini, mari kita lihat perubahan posisi ABBV, untuk kumpulan pengajuan 13F terbaru ini:

Dalam hal saham yang dimiliki, kami menghitung 14 dari dana di atas yang telah meningkatkan posisi ABBV yang ada dari 12/31/2025 hingga 03/31/2026, dengan 15 yang mengurangi posisi mereka dan 1 posisi baru. Perlu dicatat bahwa Capital Advisory Group Advisory Services LLC, dan Bright Futures Wealth Management LLC., yang termasuk dalam kumpulan terbaru pengajuan 13F ini, keluar dari saham umum ABBV pada 03/31/2026.

Melihat melampaui dana-dana tertentu dalam kumpulan terbaru para pengajuan ini, kami menjumlahkan jumlah saham ABBV secara agregat di antara *semua* dana yang memegang ABBV pada periode pelaporan 03/31/2026 (dari 793 yang kami lihat secara total). Kami kemudian membandingkan angka tersebut dengan total jumlah saham ABBV yang dipegang oleh dana-dana yang sama pada periode 12/31/2025, untuk melihat bagaimana jumlah saham agregat yang dipegang oleh hedge fund telah bergerak untuk ABBV. Kami menemukan bahwa antara kedua periode ini, dana meningkatkan kepemilikan mereka sebesar 767.646 saham secara agregat, dari 13.068.029 hingga 13.835.675 untuk peningkatan jumlah saham sekitar 5,87%. Tiga dana teratas secara keseluruhan yang memegang ABBV pada 03/31/2026 adalah:

| » | Fund | Saham ABBV yang Dipegang |
|---|---|---|
| 1. | Artemis Investment Management LLP | 1.041.483 |
| 2. | Hamlin Capital Management LLC | 836.466 |
| 3. | HM Payson & Co. | 601.712 |
| 4-10 | Cari tahu 10 Hedge Fund Teratas Lengkap yang Memegang ABBV | » |

Kami akan terus mengikuti pengajuan 13F terbaru oleh manajer hedge fund dan memberi Anda cerita menarik yang berasal dari pandangan ke informasi agregat di seluruh kelompok manajer antara periode pengajuan. Sementara melihat pengajuan 13F individu terkadang dapat menyesatkan karena sifat informasi hanya long, total keseluruhan di seluruh *kelompok* dana dari satu periode pelaporan ke periode berikutnya dapat lebih mengungkapkan dan relevan, memberikan ide saham yang menarik yang layak untuk penelitian lebih lanjut, seperti AbbVie Inc (Simbol: ABBV).

10 Komponen S&P 500 Hedge Funds Sedang Membeli »

##### Juga lihat:

Artikel Holdings Channel

Dana Memegang MOMO

Daftar Saham Dividen Barang Konsumen

Pandangan dan opini yang diungkapkan di sini adalah pandangan dan opini penulis dan tidak selalu mencerminkan pandangan Nasdaq, Inc.

Diskusi AI

Empat model AI terkemuka mendiskusikan artikel ini

Pandangan Pembuka
G
Gemini by Google
▬ Neutral

"Institutional accumulation in 13F filings is a lagging indicator that fails to account for the fundamental execution risks of AbbVie's post-Humira growth strategy."

The 5.87% aggregate increase in ABBV shares held by 793 funds suggests institutional confidence, but investors should be wary of reading too much into 13F filings. AbbVie is currently navigating a post-Humira patent cliff and the integration of ImmunoGen and Cerevel Therapeutics. While institutional accumulation signals a defensive rotation into high-yield pharma, the exit of smaller advisory firms like Capital Advisory Group may reflect tactical profit-taking after the stock's recent volatility. Investors should focus less on these aggregate flows and more on the Q2 pipeline readouts for Skyrizi and Rinvoq, which are the true drivers of long-term EPS growth, rather than lagging indicators from stale Q1 data.

Pendapat Kontra

The aggregate increase in shares could simply be a mechanical result of fund inflows rather than a deliberate, bullish conviction call on AbbVie's R&D pipeline.

ABBV
G
Grok by xAI
▬ Neutral

"13F changes indicate mild institutional nibbling at ABBV but represent too tiny a stake with too many blind spots to merit a strong directional bet."

13F filings reveal a modest 5.87% aggregate increase in ABBV long holdings to 13.8M shares across 793 funds from Q4 2025 to Q1 2026, with 14 of 51 recent filers adding vs. 15 trimming and two minor exits by Capital Advisory and Bright Futures. Directionally positive amid pharma's defensive appeal, but this equates to just 0.8% of ABBV's ~1.76B shares outstanding—negligible ownership by non-activist managers like Artemis. 13Fs ignore shorts, lag 45+ days post-quarter, and overlook ABBV's core story: Humira cliff offset by Skyrizi/Rinvoq ramp. Weak signal; prioritize Q2 earnings beats for conviction.

Pendapat Kontra

Hedge fund clusters increasing longs often spark momentum rallies, especially for high-yield dividend aristocrats like ABBV (4%+ yield) in volatile markets, outweighing the filing noise.

ABBV
C
Claude by Anthropic
▬ Neutral

"Aggregate hedge fund buying of 5.87% in Q1 2026 is consistent with passive rebalancing into a large-cap dividend stock, not a contrarian buy signal, and tells us nothing about ABBV's fundamental trajectory or relative valuation."

The article conflates modest aggregate buying (5.87% increase, 767k shares) with meaningful signal. Two funds exiting is presented neutrally but suggests selective skepticism. Critically: 13F data lags by 45 days, so Q1 filings reflect positions taken before late March. ABBV's pharma fundamentals—patent cliffs, pipeline risk, dividend sustainability—aren't addressed. Hedge fund herding into a $280B dividend stock isn't contrarian; it's momentum chasing. The article's own caveat about hidden short positions undermines the bullish framing. Without knowing ABBV's Q1 earnings trajectory or sector rotation context, aggregate buying could simply reflect rebalancing, not conviction.

Pendapat Kontra

If 34 of 51 recent filers hold ABBV and aggregate positions grew 5.87% Q1, that's genuine institutional accumulation in a mature healthcare name—precisely the kind of boring, dividend-backed stability funds rotate into during uncertainty. The two exits may reflect portfolio optimization, not bearish signals.

ABBV
C
ChatGPT by OpenAI
▬ Neutral

"13F activity is not a reliable bullish signal for ABBV; the stock’s upside remains contingent on Humira biosimilar risk and pipeline execution."

The 13F data shows a modest, potentially cautious tilt toward ABBV: 14 of the latest filers increased, 15 decreased, and 1 opened a new position, with aggregate ABBV holdings up about 5.87% versus 12/31/2025. Two notable exits (Capital Advisory Group Advisory Services and Bright Futures Wealth Management) hint at rotation rather than a uniform conviction. But 13Fs are backward-looking, long-only snapshots; they rarely predict near-term catalysts. ABBV’s fate remains tied to Humira’s biosimilar erosion, and progress from Skyrizi/Rinvoq, regulatory/pricing dynamics, and overall healthcare capex. A cautious stance is warranted until more forward-looking signals emerge.

Pendapat Kontra

Counterpoint: the uptick could be noise—13Fs are often index or liquidity-driven, not a true conviction signal. The real risk is continued biosimilar pressure on Humira and slower-than-expected pipeline growth, which could hurt ABBV’s multiple expansion.

ABBV (AbbVie) stock
Debat
G
Gemini ▼ Bearish
Menanggapi Claude

"AbbVie's recent M&A spree has weakened its balance sheet, making its dividend-backed stability less certain than historical metrics suggest."

Claude is right about the noise, but we are all missing the capital structure risk. AbbVie’s aggressive M&A strategy—specifically the $10B+ ImmunoGen and Cerevel deals—has materially altered its leverage profile. While everyone fixates on the Humira cliff, the real risk is the interest coverage ratio if these acquisitions fail to deliver immediate accretive growth. Institutional accumulation may just be a defensive play for the 4% yield, ignoring that the balance sheet is less fortress-like than it was two years ago.

G
Grok ▬ Neutral
Menanggapi Gemini

"AbbVie's M&A is guided EPS accretive with ample FCF buffer, muting near-term leverage risks despite higher debt."

Gemini's leverage warning is valid post-$10.1B ImmunoGen/$8.7B Cerevel deals (net debt ~$55B), but ABBV guided both as 2025 EPS accretive, with FCF ($18B+ projected) covering 4.3% dividend (2.5x) and $10B+ paydown. Panel overlooks this: institutions' 5.87% accumulation post-Q1 reflects priced-in resilience, not ignorance. True blind spot—botched integration delays could spike coverage ratio below 3x.

C
Claude ▼ Bearish
Menanggapi Grok
Tidak setuju dengan: Grok

"Institutional buying reflects priced-in M&A accretion, not de-risked execution; timing mismatches between debt service and synergy realization are the true leverage trap."

Grok's FCF math masks a timing risk Gemini flagged. Yes, $18B FCF covers the dividend 2.5x—on paper. But ImmunoGen and Cerevel close in 2024-2025; integration synergies typically lag 18-24 months. If Q2-Q3 earnings disappoint or pipeline delays emerge, FCF could compress sharply while debt service remains fixed. The 5.87% institutional accumulation may reflect *past* confidence in guidance, not forward visibility into whether those synergies materialize. That's the real stress test.

C
ChatGPT ▼ Bearish
Menanggapi Gemini
Tidak setuju dengan: Gemini

"ABBV's leverage and timing risk from ImmunoGen and Cerevel could squeeze FCF and cap upside if synergies lag and rates rise."

Gemini's leverage warning is valid post-deals, but the real risk is timing, not just debt level. If ImmunoGen and Cerevel synergies lag 18–24 months, FCF could dip from the ~$18B run-rate, pressuring interest coverage toward 3x or lower. In a rising-rate backdrop with net debt around $55B, covenant pressure and slower deleveraging could cap ABBV's multiple expansion even if Skyrizi/Rinvoq growth continues.

Keputusan Panel

Tidak Ada Konsensus

Despite a modest increase in institutional holdings, the panel is cautious about AbbVie's future due to the looming Humira patent cliff, integration risks from recent acquisitions, and potential capital structure issues. They advise focusing on Q2 earnings and pipeline progress rather than relying on 13F filings.

Peluang

Successful integration and growth of the Skyrizi and Rinvoq pipelines could offset the Humira patent cliff and drive long-term EPS growth.

Risiko

Integration delays or failures of recent acquisitions (ImmunoGen and Cerevel) could spike the interest coverage ratio below 3x, pressuring the balance sheet and potentially capping multiple expansion.

Berita Terkait

Dividen Farmasi Ini Telah Ditingkatkan Setiap Tahun Selama Lebih Dari Satu Dekade

Nasdaq · 1 minggu lalu

Haruskah Anda Membeli Saham AbbVie Sebelum 29 April?

Nasdaq · 1 minggu, 1 hari lalu

Loar Holdings Inc. (LOAR): Miliarder David Abrams Adalah Pengagum Besar Saham Ini

Yahoo Finance · 2 minggu, 4 hari lalu

ABBV- Saham Pendapatan Menarik di Pasar yang Kacau Ini

Yahoo Finance · 2 minggu, 4 hari lalu

Mengapa Saham AbbVie Terlihat Seperti Beli Murah Saat Ini

Nasdaq · 3 minggu, 2 hari lalu
Ini bukan nasihat keuangan. Selalu lakukan riset Anda sendiri.